The aim of the Symposium is to present the further progress of the research on Alternating Hemiplegia of Childhood (AHC), after the finding of the ATP1A3 gene as the primary cause of this rare neurological disease, to promote the international collaboration and to recruit new teams of researchers.
With respect to the clinical aspects, one session of the meeting will focus on genotype/phenotype correlations based on reports from different research groups who have studied patients from all over the world.
Similarly to what was programmed in the previous ATP1A3 Symposium in Brussels, two sessions will be dedicated to the modelling of AHC and to the results of functional studies on ATP1A3, both normally and in disease.
Finally, a new session has been programmed this year, which deals with the pharmacological modulation of ATP1A3 through different compounds that are currently used in the clinical practice for the treatment of other conditions. We hope that the discussion around this topic can pave the way towards the establishment of clinical trials for AHC.
Last, but not least, we want to express our gratitude for the crucial and generous effort of the family support groups in the organization of this Symposium.
We look forward to seeing you in Rome,
Giovanni Neri and David Goldstein, Chairmen